Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

Monterubbianesi, Rita; Aratari, Annalisa; Armuzzi, Alessandro; Daperno, Marco; Biancone, Livia; Cappello, Maria; Annese, Vito; Riegler, G.; Orlando, Ambrogio; Viscido, Angelo; Meucci, G.; Gasbarrini, Antonio; Guidi, L.; Lavagna, A.; Sostegni, R.; Onali, S.; Papi, Claudio; Kohn, Anna

doi:10.1016/j.crohns.2014.01.006

Cited by 56 publications

(42 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High levels of CRP on admission and at the time of infliximab therapy initiation have been associated with colectomy . A Danish retrospective study reviewed the records of 56 patients with acute steroid‐refractory UC, who received infliximab as rescue therapy .…”

Section: Predictors Of Response To Salvage Therapymentioning

confidence: 99%

Review article: the practical management of acute severe ulcerative colitis

Seah

Cruz

2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Review: practical management of acute severe ulcerative colitis excluded if patients had a subsequent diagnosis of Crohn's disease or indeterminate colitis. PREDICTING DISEASE COURSE AND REQUIREMENT FOR SALVAGE THERAPYOptimal management of ASUC relies on timely and repeated evaluation of disease response to therapy, in order to improve clinical outcomes. One of the major challenges faced by clinicians is the absence of a widely accepted management and monitoring protocol. 11,12 In particular, three key stages of assessment in the acute setting have been investigated in the literature: (i) on admission, (ii) after initiation of steroid therapy and (iii) after initiation of salvage therapy. More recently, studies have also focussed on long-term outcomes; however, further prospective studies in this area are required. Steroid therapy

show abstract

Section: Predictors Of Response To Salvage Therapymentioning

confidence: 99%

Review article: the practical management of acute severe ulcerative colitis

Seah

Cruz

2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The first one is infliximab (IFX), a chimeric monoclonal immunoglobulin G1 that induces clinical remission and mucosal healing, reduces the risk of colectomy, and is cost-effective in the treatment of moderate-to-severe UC. 14,15 It has been shown to be as effective as cyclosporine in the treatment of severe steroidresistant UC. 16 IFX optimization, which consists in the increase of the dose from 5 to 10 mg/kg, is useful when a clinical remission cannot be reached with a single dose.…”

mentioning

confidence: 99%

Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis

Pillet

Jarlot

Courault

et al. 2015

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Failure to achieve remission with IV steroids in 3 days is associated with ongoing failure of this treatment strategy, so additional therapy with infliximab or calcineurin inhibitors should be considered [ 39 ].…”

Section: Brief Review Of the Literaturementioning

confidence: 98%